| Cost-effectiveness of anticoagulants for suspected heparin-induced thrombocytopenia in the United States A Aljabri, Y Huckleberry, JH Karnes, M Gharaibeh, HI Kutbi, Y Raz, S Yun, ... Blood, The Journal of the American Society of Hematology 128 (26), 3043-3051, 2016 | 40 | 2016 |
| Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer M Gharaibeh, A McBride, JL Bootman, H Patel, I Abraham Journal of Medical Economics 20 (4), 345-352, 2017 | 35 | 2017 |
| Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer S Loibl, D Loirat, SM Tolaney, K Punie, M Oliveira, HS Rugo, A Bardia, ... European Journal of Cancer 178, 23-33, 2023 | 28 | 2023 |
| Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators JP Jansen, D Incerti, A Mutebi, D Peneva, JP MacEwan, B Stolshek, ... Journal of Medical Economics 20 (7), 703-714, 2017 | 28 | 2017 |
| Economic evaluation for USA of systemic chemotherapies as first-line treatment of metastatic pancreatic cancer M Gharaibeh, A McBride, DS Alberts, M Slack, B Erstad, N Alsaid, ... Pharmacoeconomics 36, 1273-1284, 2018 | 22 | 2018 |
| Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer M Gharaibeh, A McBride, JL Bootman, I Abraham British Journal of Cancer 112 (8), 1301-1305, 2015 | 22 | 2015 |
| Treatment patterns in rheumatoid arthritis patients newly initiated on biologic and conventional synthetic disease-modifying antirheumatic drug therapy and enrolled in a North … PJ Mease, S Stryker, M Liu, B Salim, S Rebello, M Gharaibeh, DH Collier Arthritis research & therapy 23, 1-13, 2021 | 16 | 2021 |
| 257P Health-related quality of life (HRQoL) in the ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC) S Loibl, D Loirat, SM Tolaney, K Punie, M Oliveira, HS Rugo, A Bardia, ... Annals of Oncology 32, S472-S473, 2021 | 16 | 2021 |
| Effectiveness and costs among rheumatoid arthritis patients treated with targeted immunomodulators using real-world US data M Gharaibeh, M Bonafede, D McMorrow, EJM Hernandez, BS Stolshek Journal of Managed Care & Specialty Pharmacy 26 (8), 1039-1049, 2020 | 13 | 2020 |
| Treatment patterns and costs in biologic DMARD-naive patients with rheumatoid arthritis initiating etanercept or adalimumab with or without methotrexate J Tkacz, M Gharaibeh, KH DeYoung, K Wilson, D Collier, H Oko-Osi Journal of Managed Care & Specialty Pharmacy 26 (3), 285-294, 2020 | 11 | 2020 |
| Economic evaluations of first-line chemotherapy regimens for pancreatic cancer: a critical review M Gharaibeh, JL Bootman, A McBride, J Martin, I Abraham Pharmacoeconomics 35, 83-95, 2017 | 11 | 2017 |
| 1553O Health-related quality of life (HRQoL) in the phase III TROPiCS-02 trial of sacituzumab govitecan (SG) vs chemotherapy in HR+/HER2-metastatic breast cancer (MBC) HS Rugo, P Schmid, SM Tolaney, F Dalenc, F Marmé, L Shi, W Verret, ... Annals of Oncology 33, S1258, 2022 | 6 | 2022 |
| Persistence of tumor necrosis factor inhibitor or conventional synthetic disease-modifying antirheumatic drug monotherapy or combination therapy in psoriatic arthritis in a … PJ Mease, NA Accortt, S Rebello, CJ Etzel, RW Harrison, GA Aras, ... Rheumatology international 39 (9), 1547-1558, 2019 | 6 | 2019 |
| Abstract P5-16-01: Assessment of health-related quality of life by clinical response from the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC) S Loibl, SM Tolaney, K Punie, M Oliveira, HS Rugo, A Bardia, SA Hurvitz, ... Cancer Research 82 (4_Supplement), P5-16-01-P5-16-01, 2022 | 4 | 2022 |
| The effect of dose escalation on the cost-effectiveness of etanercept and adalimumab with methotrexate among patients with moderate to severe rheumatoid arthritis D Incerti, EJM Hernandez, J Tkacz, JP Jansen, D Collier, M Gharaibeh, ... Journal of Managed Care & Specialty Pharmacy 26 (10), 1236-1242, 2020 | 4 | 2020 |
| Optimized economic evaluation for the United States (US) of nab-paclitaxel plus gemcitabine (NAB-P+GEM), FOLFIRINOX (FFX), and gemcitabine (GEM) as first-line treatment for … IA Mahdi Gharaibeh, Ali McBride, J. Lyle Bootman, Hitendra Patel J Clin Oncol 34 (abstr 4113), 2016 | 4 | 2016 |
| Incorporating adjustments for variability in control group response rates in network meta-analysis: a case study of biologics for rheumatoid arthritis C Cameron, A Varu, A Lau, M Gharaibeh, M Paulino, R Rogoza BMC medical research methodology 19, 1-10, 2019 | 3 | 2019 |
| Ex ante economic evaluation of genetic testing for the ARG389 beta1-adrenergic receptor polymorphism to support bucindolol treatment decisions in Stage III/IV heart failure NS Alkhatib, K Ramos, M Slack, B Erstad, M Gharaibeh, W Klimecki, ... Expert Review of Precision Medicine and Drug Development 3 (5), 319-329, 2018 | 3 | 2018 |
| Influence of Health and Functional Status and Co-occurring Chronic Conditions on Healthcare Expenditures Among Community-dwelling Adults With Kidney Cancer in the United States … S Bhattacharjee, M Gharaibeh, MU Kamal, IB Riaz Clinical Genitourinary Cancer 15 (3), e357-e368, 2017 | 3 | 2017 |
| Weibull and exponential proportional hazard modelling for optimizing economic evaluations of cancer treatments: FOLFIRINOX (FFX) vs gemcitabine (GEM) in metastatic pancreas … M Gharaibeh, H Patel, A McBride, JL Bootman, I Abraham Journal of Clinical Oncology 34 (15_suppl), e15704-e15704, 2016 | 3 | 2016 |
